In Zusammenarbeit mit dem IMMS und weiteren regionalen Partnern konnte Dr. Friedrich Scholz (Senova, Weimar) in den vergangenen Monaten dazu beitragen, biologisch-mikroelektronische In-vitro Diagnostik zum quantitativen Nachweis von Darm- und Prostatakrebs zu entwickeln. Das Unternehmen ELEKTRONIKPRAXIS aus Würzburg hat dazu diesen aufschlussreichen Artikel verfasst: Wie Mikroelektronik dabei hilft, Krebs im Frühstadium zu erkennen

      Senova ist dankbar dafür, dass dieses wichtige Vorhaben vom Freistaat Thüringen unter der Nummer 2015 FE 9159 gefördert und durch Mittel der Europäischen Union im Rahmen des Europäischen Fonds für regionale Entwicklung (EFRE) kofinanziert werden konnte. 

 

 

 

Besuchen Sie uns am 17.11.2017 in der Industriestraße 8 in Weimar? Sie sind herzlich willkommen, uns über die Schulter zu schauen: Zwischen 18:00 Uhr und 23:45 Uhr finden jeweils zur vollen Stunde Führungen rund um das Thema Schnelltest-Entwicklung und -Produktion statt. Wir freuen uns auf Ihren Besuch! Vor-Anmeldung möglich unter Tel. 03643 8559379 (Katharina Lindacher)

 

Preisverleihung

18.09.2017

Das Senova Team gratuliert seinem Firmeninhaber Hans Hermann Söffing zu einer besonderen Auszeichnung: Der Bundesverband mittelständische Wirtschaft übergab den Preis "Unternehmer des Jahres 2017 der Stadt Weimar" im neuen Senova Geschäftsgebäude in der Industriestaße 8, Weimar.

Viele Wegbegleiter von Herrn Söffing waren zur feierlichen Preisverleihung gekommen und freuten sich gemeinsam mit ihm über die herzerwärmenden Begrüßung von Senova-Geschäftsführer Andreas Gütter sowie über die gelungene Laudatio von Oberbürgermeister Stefan Wolf. Für die ausgezeichnete Verpflegung sorgte die Crew vom Uhrenwerk Catering - das war wohl die kürzeste Anfahrt überhaupt zu einem Catering, denn das köstliche Essen kam somit direkt vom Nachbargelände der Senova!

Der Dank gilt dem BVMW mit seinen Vertretern Herrn Horst Schulze und Herrn Ringo Siemon für die Organisation - es war wirklich ein gelungener Tag und noch dazu eine wohlverdiente Verschnaufpause vom Baulärm. Lesen Sie hier mehr über die Preisverleihung:

Bericht Unternehmer des Jahres der Stadt Weimar 2017

Verbesserung der Präanalytik und Analytik für In-vitro Diagnostik

Safety Sample ist ein Werkzeug, das in Bezug auf die Probenahme viele Vorstufen eines Schnelltests in sich vereint, um eine sichere Präanalytik zu gewährleisten und darüber hinaus die Analytik von In-vitro Diagnostik zu verbessern. Durch den modularen Probenehmer können Proben von der Fingerbeere, per Pipettenspitze oder mit einer Kanüle aufgenommen werden. Die Integration verschiedener Speichermodule soll eine immunologische Probenseparation, einen möglichen Antigenaufschluss und eine Vorinkubation von Proben ermöglichen.

Safety Sample befindet sich derzeit im Prototyping. Die technische Machbarkeitsuntersuchung wurde erfolgreich abgeschlossen.

 

 

Das diesen Ergebnissen zugrundeliegende Vorhaben wurde vom Freistaat Thüringen unter der  Nummer 2016 IDS 0030 gefördert und durch Mittel der Europäischen Union im Rahmen des Europäischen Fonds für regionale Entwicklung (EFRE) kofinanziert.

 

 

 

 

 

 

 

 

 

For more than 10 years, our company deals with the detection of biohazardous materials.

The Ebola virus always played a primary role and we see us confirmed in the decision to have pursued this theme consistently in cooperation with our partners.

Currently an Ebola lateral flow screening test developed in recent years is being evaluated with real specimens in Gueckedou (Guinea). 

As soon as the evaluation shows a successful result, Senova will be able to provide this test to all affected regions. A quality screening test has the potential to make the quarantine management dramatically more efficient and to be able to immediately respond to the risk of infection in case of emergency.

We thank our partners who have supported us in the development, validation and Support:

Institut für Mikrobiologie der Bundeswehr

Institut für Virologie der Philipps-Universität Marburg

Bernhard-Nocht-Institut für Tropenmedizin Hamburg

 

July 2014: The new website Senova

The new Senova site is live - a digital platform where striking communication is possible about all topics Senova is dedicated to. Main task is the need-based sales approach. With a clean design, a clear navigation and links to the new web shop, the Usability of the content has been significantly improved. The technologies used and the services offered are explained clearly. Senova is proud of the team work and is pleased to present itself to the interested visitors of the site in an attractive online appearance.

 

December 2013: New division coagulation diagnostics

With the acquisition of significant assets of JenAffin, Senova GmbH expands its portfolio of innovative technologies, patents and products in the field of in-vitro diagnostics of blood coagulation. Building on the acquisition of knowledge sources and the industrial and academic network Senova will continue to develop and expand this line of business. Particular attention will be paid to the requirements of laboratory diagnostics that occur with the introduction of new drugs such as direct oral anticoagulants (thrombin and factor Xa inhibitors). The offered range of instruments for your treatment decision, treatment monitoring and treatment optimization is large. Learn all about the tools you need on the subject of coagulation diagnostics here.

April 2013: Launch of the DEDIACARD Cardio

In cooperation with "Devidia Deutsche Vitaldiagnostik" Senova succeeded in producing a greatly improved rapid test for myocardial infarction, which is now available in Germany. After evaluating current poll results with private practitioners and clinics, valuable improvements could be considered in terms of reliability and speed for this test. Because unlike to the conventional troponin I test, which is already established in addition to the ECG, the "Dediacard Cardio" may detect an ischemic incident only 20 min. after the event. This is made possible by a second biomarker, the hFABP, which is applied to the test Strip in Addition to troponin I. The handling of the black cartridge tests in check card format will delight the professional user, because with only one drop of blood from the fingertip of the patient the diagnosis of myocardial infarction will either be confirmed or excluded within 10 min. The legal documentation is facilitated by a removable label which completes the patient record. "We are thankful that Senova worked with us that ambitiously on the topic of ​​infarction diagnosis," Sebastian Kellner, CEO of Devidia GmbH, says: "... because with the now available research results, we can provide doctors with another important tool for a life-saving diagnosis in certain circumstances. We are sure that our customers will appreciate this product from German research and quality manufacturing. "

 

January 2013: IVD control material available now

Based on the known abicap column we can offer lyophilized control material for our customers from now on. In our webshop you will find some components already available. Other material for your project may be obtained on request. Our team looks forward to your inquiry.

May 2012: IVD product range extended

With the introduction of cassette and strip tests with important biomarkers such as HCG, Strep A, microalbumin, Influenza A + B and LH, Senova complements its product line of immunological rapid tests. These are established markers used in everyday practice of general practitioners and  several specialists. "This new Senova program is an important addition to the existing ordinary products," CEO Hans Hermann Söffing says: "We are very proud to be able to provide our customers with more tools for a solid diagnosis." Based on the latest medical technology knowledge, the existing product range is continually being expanded. Senova, using the knowledge and experience of its staff, will continue to develop innovative new products from German manufacturing.

December 2011: TÜV certification successfully completed 

TÜV Rheinland confirmed that Senova met all requirements for the EN ISO 9001:2008 certification. This enables the company to develop, to produce and to distribute immunological rapid test systems for in vitro diagnostics in Germany. As first European company Senova can rely on an all-digital quality management system with full batch traceability. This means that all parts and components are traceable in the system. This enables us to retrace and thus explain any possible customer complaints completely.

September 2011: Helicobacter pylori rapid test developed

In cooperation with the Research Center for Medical Technology and Biotechnology Bad Langensalza a innovative proof of bacterium Helicobacter pylori was developed in tissue samples. Urea, which is existing in the test medium, is decomposed in ammonia and carbon dioxide in case of the presence of Helicobacter pylori, which leads to a pH increase. This pH shift is made visible by the phenol red indicator dye which changes color from yellow to red. Thus, the presence of Helicobacter pylori can be detected directly. Due to the simple test construction an easy handling for the user is guaranteed. In comparison to the competing product Jatrox H.P. the test medium is already presented in the reaction vessel, resulting in time savings. In addition, no further aids, for example forceps, are required to bring the test tablet into the reaction vessel. The reaction vessel only needs to be prepared with the tissue sample from the prepyloric antrum and the distilled water (which is contained in the kit). The evaluation of the assay is very easy. A color change indicates a positive result. If the color remains unchanged during the specified reaction time, it can be assumed that the test result is negative. The maximum evaluation time is 24 hours. However, the result can be read in most patients already after 30 minutes. The storage requirements for these rapid tests are simple: In a dry environment at room temperature, a shelf life of 24 months is guaranteed.

May 2010: New plant opened

With the construction of the new plant in Weimar, the city of poets, the Senova team met a big dream. The significantly grown team of currently 25 employees in research, development and production is pleased with the new location in the Industriestrasse: On the site of a former swiss clock factory, 1200 m² of modern laboratories, optimized production rooms and comfortable offices grew within only a few months. The sophisticated designed production areas allow the production of up to 30 million test strips per year. Strengthened by the repositioning Senova can meet the market needs even better now. The company will commit itself to its customers further on.

October 2009: lateral flow assays developed

In cooperation with its partners Servoprax (Wesel) and Wörner Medical Devices (Reutlingen) Senova starts the development of high quality rapid tests for medical practices. Troponin I, FOB and D-dimer are the first biomarkers that are selected for the production of strip tests from German production. The aim is to actually give lateral flow tests the value in the doctor's office again that they once had lost in the market due to lack of reliability of some previous products. As a result, the practical laboratory can play a bigger role again. A plus point for physicians who want to break away from the laboratory dependence and associated long analysis times for critical emergency parameters. Expanding their scope of action and assuring any diagnosis is now facilitated by the reliable point-of-care diagnostics from Senova.